UK markets open in 3 hours 43 minutes

NuCana plc (NCNA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.8000+0.0127 (+1.61%)
At close: 04:00PM EDT
0.7220 -0.08 (-9.75%)
After hours: 05:15PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.7873
Open0.7900
Bid0.7950 x 800
Ask0.8500 x 1300
Day's range0.7630 - 0.8399
52-week range0.5170 - 3.3200
Volume97,410
Avg. volume160,901
Market cap41.757M
Beta (5Y monthly)0.59
PE ratio (TTM)N/A
EPS (TTM)-0.9200
Earnings date17 Aug 2022 - 22 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est759.56
  • Globe Newswire

    NuCana Announces Presentation on NUC-7738 at the European Hematology Association (EHA) 2022 Hybrid Congress

    NUC-7738 Shows Promising Non-Clinical Activity in Acute Myeloid Leukemia NUC-7738 Kills AML Cells Resistant to Standard Chemotherapy Data Indicates Potential Clinical Utility Beyond Solid Tumors EDINBURGH, United Kingdom, June 10, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced data to be presented at the European Hematology Association (EHA) 2022 Hybrid Congress highlighting the activity of NUC-7738, a phosphoramidate transformation of 3’-deoxyadenosine (3’-dA), in a broad range of

  • Globe Newswire

    NuCana Announces Receipt of NASDAQ Notice

    EDINBURGH, United Kingdom, June 03, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that it received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC ("Nasdaq") dated May 27, 2022, indicating that, based upon a closing bid price of less than $1.00 per share for the Company’s American Depositary Shares (“ADSs”) for the prior 30 consecutive business day period, the Company no longer satisfies Nasdaq Listing Rule 5450(a)(1). The Notification Letter has

  • Globe Newswire

    NuCana Reports First Quarter 2022 Financial Results and Provides Business Update

    Initiated Randomized Phase 2 Study of NUC-3373 in Patients with Colorectal Cancer Initiated Phase 1b/2 Study of NUC-3373 in Combination with Other Agents, Including PD-1 Inhibitors, in Patients with Solid Tumors First Patients Enrolled in Phase 2 Study of NUC-7738 Multiple Data Readouts in 2022 Well Capitalized with Anticipated Cash Runway into 2025 EDINBURGH, United Kingdom, June 02, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the first quarter ended March